These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33997893)

  • 1. SynLeGG: analysis and visualization of multiomics data for discovery of cancer 'Achilles Heels' and gene function relationships.
    Wappett M; Harris A; Lubbock ALR; Lobb I; McDade S; Overton IM
    Nucleic Acids Res; 2021 Jul; 49(W1):W613-W618. PubMed ID: 33997893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive clinically informed map of dependencies in cancer cells and framework for target prioritization.
    Pacini C; Duncan E; Gonçalves E; Gilbert J; Bhosle S; Horswell S; Karakoc E; Lightfoot H; Curry E; Muyas F; Bouaboula M; Pedamallu CS; Cortes-Ciriano I; Behan FM; Zalmas LP; Barthorpe A; Francies H; Rowley S; Pollard J; Beltrao P; Parts L; Iorio F; Garnett MJ
    Cancer Cell; 2024 Feb; 42(2):301-316.e9. PubMed ID: 38215750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-omic measurement of mutually exclusive loss-of-function enriches for candidate synthetic lethal gene pairs.
    Wappett M; Dulak A; Yang ZR; Al-Watban A; Bradford JR; Dry JR
    BMC Genomics; 2016 Jan; 17():65. PubMed ID: 26781748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality.
    Parameswaran S; Kundapur D; Vizeacoumar FS; Freywald A; Uppalapati M; Vizeacoumar FJ
    Trends Cancer; 2019 Jan; 5(1):11-29. PubMed ID: 30616753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignancy of Cancers and Synthetic Lethal Interactions Associated With Mutations of Cancer Driver Genes.
    Wang X; Zhang Y; Han ZG; He KY
    Medicine (Baltimore); 2016 Feb; 95(8):e2697. PubMed ID: 26937901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer.
    Tang YC; Ho SC; Tan E; Ng AWT; McPherson JR; Goh GYL; Teh BT; Bard F; Rozen SG
    Breast Cancer Res; 2018 Mar; 20(1):22. PubMed ID: 29566768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets.
    Guo J; Liu H; Zheng J
    Nucleic Acids Res; 2016 Jan; 44(D1):D1011-7. PubMed ID: 26516187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying synthetic lethal targets using CRISPR/Cas9 system.
    Dhanjal JK; Radhakrishnan N; Sundar D
    Methods; 2017 Dec; 131():66-73. PubMed ID: 28710008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An in-silico approach to predict and exploit synthetic lethality in cancer metabolism.
    Apaolaza I; San José-Eneriz E; Tobalina L; Miranda E; Garate L; Agirre X; Prósper F; Planes FJ
    Nat Commun; 2017 Sep; 8(1):459. PubMed ID: 28878380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
    Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
    BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic synthetic lethality approaches in cancer therapy.
    Yang H; Cui W; Wang L
    Clin Epigenetics; 2019 Oct; 11(1):136. PubMed ID: 31590683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualized genetic network analysis reveals new therapeutic vulnerabilities in 6,700 cancer genomes.
    Liu C; Zhao J; Lu W; Dai Y; Hockings J; Zhou Y; Nussinov R; Eng C; Cheng F
    PLoS Comput Biol; 2020 Feb; 16(2):e1007701. PubMed ID: 32101536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SynLethDB 2.0: a web-based knowledge graph database on synthetic lethality for novel anticancer drug discovery.
    Wang J; Wu M; Huang X; Wang L; Zhang S; Liu H; Zheng J
    Database (Oxford); 2022 May; 2022():. PubMed ID: 35562840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of synthetic lethality based on a functional network by using machine learning algorithms.
    Li J; Lu L; Zhang YH; Liu M; Chen L; Huang T; Cai YD
    J Cell Biochem; 2019 Jan; 120(1):405-416. PubMed ID: 30125975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-omics characterization of synthetic lethality-related molecular features: implications for SL-based therapeutic target screening.
    Weng S; Ruan H
    FEBS J; 2023 Mar; 290(6):1477-1480. PubMed ID: 36461713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation.
    Topatana W; Juengpanich S; Li S; Cao J; Hu J; Lee J; Suliyanto K; Ma D; Zhang B; Chen M; Cai X
    J Hematol Oncol; 2020 Sep; 13(1):118. PubMed ID: 32883316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening.
    McDonald ER; de Weck A; Schlabach MR; Billy E; Mavrakis KJ; Hoffman GR; Belur D; Castelletti D; Frias E; Gampa K; Golji J; Kao I; Li L; Megel P; Perkins TA; Ramadan N; Ruddy DA; Silver SJ; Sovath S; Stump M; Weber O; Widmer R; Yu J; Yu K; Yue Y; Abramowski D; Ackley E; Barrett R; Berger J; Bernard JL; Billig R; Brachmann SM; Buxton F; Caothien R; Caushi JX; Chung FS; Cortés-Cros M; deBeaumont RS; Delaunay C; Desplat A; Duong W; Dwoske DA; Eldridge RS; Farsidjani A; Feng F; Feng J; Flemming D; Forrester W; Galli GG; Gao Z; Gauter F; Gibaja V; Haas K; Hattenberger M; Hood T; Hurov KE; Jagani Z; Jenal M; Johnson JA; Jones MD; Kapoor A; Korn J; Liu J; Liu Q; Liu S; Liu Y; Loo AT; Macchi KJ; Martin T; McAllister G; Meyer A; Mollé S; Pagliarini RA; Phadke T; Repko B; Schouwey T; Shanahan F; Shen Q; Stamm C; Stephan C; Stucke VM; Tiedt R; Varadarajan M; Venkatesan K; Vitari AC; Wallroth M; Weiler J; Zhang J; Mickanin C; Myer VE; Porter JA; Lai A; Bitter H; Lees E; Keen N; Kauffmann A; Stegmeier F; Hofmann F; Schmelzle T; Sellers WR
    Cell; 2017 Jul; 170(3):577-592.e10. PubMed ID: 28753431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR editing of sftb-1/SF3B1 in Caenorhabditis elegans allows the identification of synthetic interactions with cancer-related mutations and the chemical inhibition of splicing.
    Serrat X; Kukhtar D; Cornes E; Esteve-Codina A; Benlloch H; Cecere G; Cerón J
    PLoS Genet; 2019 Oct; 15(10):e1008464. PubMed ID: 31634348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unsupervised correction of gene-independent cell responses to CRISPR-Cas9 targeting.
    Iorio F; Behan FM; Gonçalves E; Bhosle SG; Chen E; Shepherd R; Beaver C; Ansari R; Pooley R; Wilkinson P; Harper S; Butler AP; Stronach EA; Saez-Rodriguez J; Yusa K; Garnett MJ
    BMC Genomics; 2018 Aug; 19(1):604. PubMed ID: 30103702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DiscoverSL: an R package for multi-omic data driven prediction of synthetic lethality in cancers.
    Das S; Deng X; Camphausen K; Shankavaram U
    Bioinformatics; 2019 Feb; 35(4):701-702. PubMed ID: 30059974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.